The Oncology Institute Q2 2024 GAAP EPS $(0.17) Misses $(0.09) Estimate, Sales $98.578M Miss $103.306M Estimate
Portfolio Pulse from Benzinga Newsdesk
The Oncology Institute (NASDAQ:TOI) reported Q2 2024 GAAP EPS of $(0.17), missing the $(0.09) estimate by 88.89%. Sales were $98.578M, missing the $103.306M estimate by 4.58%, but up 22.88% from last year's $80.224M.
August 13, 2024 | 8:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The Oncology Institute (NASDAQ:TOI) reported Q2 2024 GAAP EPS of $(0.17), missing the $(0.09) estimate by 88.89%. Sales were $98.578M, missing the $103.306M estimate by 4.58%, but up 22.88% from last year's $80.224M.
The significant miss on both EPS and sales estimates is likely to negatively impact TOI's stock price in the short term, despite the year-over-year sales growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100